As a number of pharmaceutical companies race to find a drug to ease the conditions of Alzheimer’s Disease, Deerfield based . has been signaled out as the only company which has found a level of success so far, according to a report on Bloomberg.
Baxter currently has Gammagard in mid stage trials and hopes to have a final phase study completed next year. Though the drug has been around for years, according to the Bloomberg report, it is scarce and expensive. Baxter hopes it will slow or stop the disease.
According to the Bloomberg report, other drugs which are in final stage trials have been a disappointment to the people involved including one man who left the other companies’ trial early because of hallucinations and headaches.